A novel soluble nano dimension polyhemoglobin-tyrosinase retards the growth of Murine B16F10 Melanoma in mice
B. Yu and T.M.S. Chang
McGill University, CA
nanocomplex melanoma polyhemoglobin-tyrosinase
Polymeric artificial cells can now be prepared in the nano dimension ranging from 1 to 100 nanometer (Chang, Nature Review Drug Discovery, 2005, 4: 221-235). We report here a novel soluble polyhemoglobin-tyrosinase complex of 1.5 to 2 nanometers and studied in an animal model of the fatal skin cancer, melanoma. This inhibits the growth of B16F10 melanoma cells cultured in DMEM. Daily intravenous injection lowers plasma tyrosine levels to 0.19 ± 0.09 mg/dl on day 2, compared to 1.44 ± 0.16 mg/dl in the control group. There was no weight loss or vomiting. When inoculated B16F10 cells in mice reach an average volume of 125mm3 on day 9, we start one of the following: (1) Sham control (2) Saline control (3) PolyHb-tyrosinase solution. Ten days later the tumor volume of the control has reached the maximal of 10% of body weight allowed by the Animal Care Committee. At this time, the tumor size in the test group was 45.28 ± 10.09% of the control group. Our results suggest that PolyHb-tyrosinase retards the growth of B16F10 melanoma in mice and suggests further studies to optimize this and also the use this in combination with other treatment methods.
Back to Program
Nanotech 2006 Conference Program Abstract